Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir‐based dual therapy. Bi‐lipid study
Sign Up to like & getrecommendations! Published in 2022 at "HIV Medicine"
DOI: 10.1111/hiv.13432
Abstract: The use of tenofovir alafenamide (TAF) has been associated with increased cholesterol and body weight. Real‐life data on the metabolic effects of switching from a TAF‐based triple regimen to a dolutegravir (DTG)‐based two‐drug regimen (2‐DR)… read more here.
Keywords: parameters switching; change metabolic; switching triple; metabolic parameters ... See more keywords